Nephrocare Health Services Ltd vs Yatharth Hospital Trauma Care Services Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Nephrocare Health Services Ltd is ₹ 597.3 as of 23 Oct 15:30 . The P/E Ratio of Nephrocare Health Services Ltd changed from 66 on March 2026 to 66 on March 2026 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Yatharth Hospital & Trauma Care Services Ltd changed from 31.3 on March 2024 to 33.9 on March 2026 . This represents a CAGR of 2.70% over 3 years The Market Cap of Nephrocare Health Services Ltd changed from ₹ 5072 crore on March 2026 to ₹ 5072 crore on March 2026 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Yatharth Hospital & Trauma Care Services Ltd changed from ₹ 3582 crore on March 2024 to ₹ 5946 crore on March 2026 . This represents a CAGR of 18.40% over 3 years The revenue of Nephrocare Health Services Ltd for the Jun '26 is ₹ 289.21 crore as compare to the Mar '26 revenue of ₹ 277.18 crore. This represent the growth of 4.34% The revenue of Yatharth Hospital & Trauma Care Services Ltd for the Jun '26 is ₹ 397.01 crore as compare to the Mar '26 revenue of ₹ 348.67 crore. This represent the growth of 13.86% The ebitda of Nephrocare Health Services Ltd for the Jun '26 is ₹ 67.78 crore as compare to the Mar '26 ebitda of ₹ 62.24 crore. This represent the growth of 8.9% The ebitda of Yatharth Hospital & Trauma Care Services Ltd for the Jun '26 is ₹ 96.04 crore as compare to the Mar '26 ebitda of ₹ 87.02 crore. This represent the growth of 10.37% The net profit of Nephrocare Health Services Ltd changed from ₹ 20.11 crore to ₹ 31.97 crore over 7 quarters. This represents a CAGR of 30.33% The net profit of Yatharth Hospital & Trauma Care Services Ltd changed from ₹ 30.38 crore to ₹ 45.42 crore over 9 quarters. This represents a CAGR of 19.57% The Dividend Payout of Nephrocare Health Services Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Yatharth Hospital & Trauma Care Services Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Nephrocare Health Services Ltd

Nephrocare Health Services Limited was incorporated as 'Nephrocare Health Services Private Limited', a private limited company at Hyderabad with a certificate of incorporation issued by the Assistant Registrar of Companies, Andhra Pradesh on December 18, 2009.
Company was converted into a public limited company and the name was changed to 'Nephrocare Health Services Limited' with a fresh certificate of incorporation dated June 18, 2025 issued by the Registrar of Companies, Central Registration Centre. Company offer comprehensive dialysis care through a network of clinics - from diagnosis to treatment and wellness programs including haemodialysis, home and mobile dialysis, supported by pharmacy.
The Company began journey in 2010 with the launch of its first dialysis clinic in Hyderabad.
It launched first Public Private Partnership (PPP) clinic in Sananth Nagar, Hyderabad in 2012; acquired 100% stake in DaVita Care (India) Private Limited, the Indian arm of DaVita Care Pte Ltd.

About Yatharth Hospital & Trauma Care Services Ltd

Yatharth Hospital & Trauma Care Services Limited was formerly incorporated as a Private Limited Company in Delhi dated February 28, 2008.
On November 3, 2021, the status converted into a Public Company and name of the Company was changed to Yatharth Hospital & Trauma Care Services Limited' on November 18, 2021 issued by the RoC. Yatharth Hospitals and Trauma Care Services Limited is a network of super speciality hospitals across Delhi National Capital Region (NCR) and Madhya Pradesh, capitalising on the robust healthcare infrastructure in these regions to serve a wide patient base in need of tertiary care. The Company operate three super specialty hospitals in Delhi NCR, i.e., at Greater Noida, Uttar Pradesh.
The super speciality tertiary care hospital currently operates with 400 beds, including 112 critical care beds and 9 modular operation theatres, among other surgical facilities.

FAQs for the comparison of Nephrocare Health Services Ltd and Yatharth Hospital & Trauma Care Services Ltd

Which company has a larger market capitalization, Nephrocare Health Services Ltd or Yatharth Hospital & Trauma Care Services Ltd?

Market cap of Nephrocare Health Services Ltd is 6,006 Cr while Market cap of Yatharth Hospital & Trauma Care Services Ltd is 8,978 Cr

What are the key factors driving the stock performance of Nephrocare Health Services Ltd and Yatharth Hospital & Trauma Care Services Ltd?

The stock performance of Nephrocare Health Services Ltd and Yatharth Hospital & Trauma Care Services Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Nephrocare Health Services Ltd and Yatharth Hospital & Trauma Care Services Ltd?

As of October 25, 2026, the Nephrocare Health Services Ltd stock price is INR ₹597.3. On the other hand, Yatharth Hospital & Trauma Care Services Ltd stock price is INR ₹931.85.

How do dividend payouts of Nephrocare Health Services Ltd and Yatharth Hospital & Trauma Care Services Ltd compare?

To compare the dividend payouts of Nephrocare Health Services Ltd and Yatharth Hospital & Trauma Care Services Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.